CareFusion Corporation (NYSE:CFN) announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1 billion. Of these notes, $300 million will mature in 2017 and will bear interest at an annual rate of 1.450 percent; $400 million will mature in 2024 and will bear interest at an annual rate of 3.875 percent and $300 million will mature in 2044 and will bear interest at an annual rate of 4.875 percent. CareFusion Corporation (NYSE:CFN) net profit margin is 10.30% and weekly performance is 4.29%. On last trading day company shares ended up $42.76. Analysts mean target price for the company is $43.45. CareFusion Corporation (NYSE:CFN) distance from 50-day simple moving average (SMA50) is 7.24%.
BMO Capital thinks the FDA’s approval of Actavis’ (ACT) generic version of Exalgo was expected, but the firm still views it as a near-term negative for Mallinckrodt PLC (NYSE:MNK). BMO expects Mallinckrodt’s raised guidance and pending accretive Questcor (QCOR) deal to support the stock longer-term and maintains an Outperform rating on Mallinckrodt. Mallinckrodt PLC (NYSE:MNK) shares advanced 3.41% in last trading session and ended the day on $78.86. MNK Gross Margin is 46.70% and its return on assets is 2.50%. Mallinckrodt PLC (NYSE:MNK) quarterly performance is 17.33%.
U.S. health regulators turned down an application to approve Novartis AG (ADR) (NYSE:NVS)’ experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday. Novartis said in a statement the Food and Drug Administration (FDA) had asked for further evidence to determine the efficacy of serelaxin, also known as RLX030. Novartis AG (ADR) (NYSE:NVS) shares moved down -0.06% in last trading session and was closed at $89.88, while trading in range of $89.50 – $90.01. Novartis AG (ADR) (NYSE:NVS) year to date (YTD) performance is 15.59%.
Hospira (NYSE:HSP) Director Barbara Bowles sold 2,000 shares of Hospira stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $47.77, for a total transaction of $95,540.00. Following the sale, the director now directly owns 26,219 shares in the company, valued at approximately $1,252,482. Hospira, Inc. (NYSE:HSP) ended the last trading day at $48.12. Company weekly volatility is calculated as 1.72% and price to cash ratio as 11.88. Hospira, Inc. (NYSE:HSP) showed a positive weekly performance of 1.31%.
Shares of Edwards Lifesciences Corp (NYSE:EW) hit a new 52-week high of $86.75, eventually Edwards Lifesciences Corp (NYSE:EW) shares advanced 0.19% in last trading session and ended the day on $86.03. EW Gross Margin is 73.60% and its return on assets is 17.70%. Edwards Lifesciences Corp (NYSE:EW) quarterly performance is 27.40%.